[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100446969":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":40,"responsibleParty":88,"collaborators":10,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":10,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":10,"enrollmentInfo":100,"targetDuration":10,"studyType":103,"phases":10,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Indiana University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-risk",null,"Low-risk:score 0-6",[13],"Diagnostic Test: Point score prediction tool for 30-day survival",{"label":15,"type":10,"description":16,"interventionNames":17},"Intermediate-risk","Intermediate-risk: score 7-13",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"High-risk","High-risk:score 14-20",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Point score prediction tool for 30-day survival","This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.\n\nThe scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days",[19,15,9],[29],{"name":30,"affiliation":5,"role":31},"Naoyuki Saito, MD PhD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Jessica Anders","CONTACT","(317) 274-0220","jemlynn@iu.edu",{"name":39,"role":35,"phone":10,"phoneExt":10,"email":10},"Naoyuki G Saito, MD PhD",[41,60,74],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"IU Health West","RECRUITING","Avon","Indiana","46123","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-86.39972,39.76282,{"lat":53,"lon":52},[56],{"name":57,"role":35,"phone":58,"phoneExt":10,"email":59},"Todd Foster","317-278-2546","tlfoster@iu.edu",{"facility":61,"status":43,"city":62,"state":45,"zip":63,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"IU Health North \u002F Schwarz Cancer Center","Carmel","46032",{"type":50,"coordinates":65},[66,67],-86.11804,39.97837,{"lat":67,"lon":66},[70],{"name":71,"role":35,"phone":72,"phoneExt":10,"email":73},"Matthew Buzzell","317-274-0925","matabuzz@iu.edu",{"facility":75,"status":43,"city":76,"state":45,"zip":77,"country":47,"countryCode":48,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Methodist Hospital","Indianapolis","46202",{"type":50,"coordinates":79},[80,81],-86.15804,39.76838,{"lat":81,"lon":80},[84],{"name":85,"role":35,"phone":86,"phoneExt":10,"email":87},"Kathy Lauer","317-962-3172","klauer@iuhealth.org",{"type":31,"investigatorFullName":89,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Naoyuki G. Saito, M.D., Ph.D.","Assistant Professor of Radiation Oncology","100446969","prospective-validation-of-a-points-score-system-predicting-30-day-survival-100446969",false,"NCT05100342","Prospective Validation of a Points Score System Predicting 30-day Survival","Prospective Validation of a Points Score System Predicting 30-day Survival for Patients With Metastatic Cancer Receiving Palliative Radiation Therapy","Inclusion Criteria:\n\n1. Age ≥ 18 at time of consent\n2. Ability to provide written informed consent\n3. Cancer diagnosis referred to Radiation Oncology for palliative radiation therapy\n4. Patients who either choose to not receive radiation therapy or not recommended to receive radiation therapy will remain eligible\n5. Those patients who undergo a course of palliative radiation therapy, it is not the requirement of this study to complete that course of treatment. Those who prematurely end their course of treatment will remain eligible Note: Patients who ultimately either choose to not receive radiation or not recommended to receive radiation will remain eligible\n\nNote: Patients who ultimately do not complete prescribed radiation will remain eligible\n\nExclusion Criteria:\n\n1. Patients who are unable to participate in follow up visits per investigator discretion (virtual\u002Fphone follow up is permitted)\n2. Patients who are receiving definitive\u002Fcurative course of radiation therapy\n3. Patients who self-report as pregnant or nursing","ALL","18 Years",{"count":101,"type":102},214,"ESTIMATED","OBSERVATIONAL","This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.",[106],"Metastatic Cancer",[108,109],"palliative radiation","radiation therapy","2026-05-05",{"date":112,"type":113},"2026-05-08","ACTUAL",{"date":115,"type":113},"2022-09-12",{"date":117,"type":102},"2027-12",{"name":5,"class":6},3]